Skip to content
Peptideworth
Menu

Goal guide

Peptides for Injury and Tendon Recovery: What the Evidence Shows

The peptides sold for tendon, ligament and muscle repair share a pattern: strong, repeatable results in rodents, and almost nothing finished in people. A 2025 systematic review of BPC-157 found 36 studies, of which 35 were preclinical. The first phase 2 trial of any of these compounds in a real sports injury began recruiting in February 2026 and is not due to complete until 2028. Until then, the animal work is the whole case.

By Grant Delaney, Research Editor
Compounds

5

RCT evidence

0

FDA-approved

0

Weak evidence

4

Ranked by evidence

What actually has evidence behind it

Ordered by how far the published human evidence goes — strongest first. Availability is a separate question from evidence, so it is labeled separately.

  1. Thymosin beta-4 (the full 43-residue protein)

    Research use only
    Early human

    Evidence strength: Early human. Small, open-label, or phase 1/2 trials. Promising, unproven.

    What it is

    A 43-residue protein involved in actin binding, cell migration and wound healing. It is the parent molecule of the fragment sold as TB-500, and it is not the same thing.

    What the evidence shows

    The published phase 3 result is ophthalmic: a randomized, placebo-controlled, double-masked trial of a 0.1% thymosin beta-4 eye drop in 18 patients with stage 2 and 3 neurotrophic keratopathy. Complete healing at four weeks occurred in 6 of 10 treated patients against 1 of 8 on placebo, which the authors reported at p = 0.0656 and described as a strong efficacy trend rather than a significant difference; healing at day 43 and disease-stage improvement did reach significance. A 2026 orthopaedic primer on injectable peptide therapy reports human orthopaedic data for this molecule as lacking.1,6

    The catch

    An eye drop in eighteen people, for a corneal defect. The route is topical, the tissue is cornea, and the sample size cannot detect an uncommon harm. As of August 2026 a ClinicalTrials.gov search for thymosin beta 4 returns 18 studies, whose listed conditions are ocular, cardiac, dermal and vascular — none of the 18 lists a tendon, ligament, joint or muscle injury.

    Sold for laboratory use. Not a legal medicine for people.

  2. BPC-157

    Compounding restricted
    Animal only

    Evidence strength: Animal only. Rodent or cell studies. Nothing published in humans.

    What it is

    A synthetic 15-amino-acid sequence derived from a protein found in gastric juice, sold for tendon, ligament and muscle healing.

    What the evidence shows

    A 2025 systematic review searched the literature to June 2024 and included 36 studies: 35 preclinical and one clinical. Across animal models it improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injury, acting on growth-hormone receptor expression, angiogenesis and inflammatory cytokines. The one clinical entry was retrospective: after intra-articular injection for unspecified chronic knee pain, 7 of 12 patients reported relief lasting more than six months. A 2025 narrative review counted three human pilot studies in total — knee pain, interstitial cystitis, and an intravenous safety and pharmacokinetics study — and reported no clinical safety data found.1,4,5

    The catch

    Thirty-five animal studies and one retrospective series of twelve people is not a basis for a decision about your own tendon. The registry position changed in 2026: as of August 2026 a ClinicalTrials.gov intervention search returns three BPC-157 studies — a 42-participant phase 1 safety and pharmacokinetics study listed with unknown status since 2016, a 120-participant phase 2 in acute hamstring muscle strain that began recruiting in February 2026 with estimated completion in February 2028, and a completed 40-participant study of a peptide gummy product measuring inflammation markers. None has posted results.

    Under active FDA restriction — compliant pharmacies decline to sell it.

  3. TB-500 (thymosin beta-4 fragment, N-acetylated LKKTETQ)

    Research use only
    Animal only

    Evidence strength: Animal only. Rodent or cell studies. Nothing published in humans.

    What it is

    The seven-residue actin-binding segment at positions 17 to 23 of thymosin beta-4, synthesised and acetylated. Seven residues of the parent protein's forty-three.

    What the evidence shows

    A 2026 orthopaedic review concluded that thymosin beta-4 and its derivative TB-500 promote angiogenesis and tissue repair in preclinical models, and that human orthopaedic data are lacking for both. A 2026 sports medicine review places TB-500 among unapproved compounds with favourable animal tissue-repair outcomes and scarce rigorous human data. A 2023 analysis of products sold over the internet as TB500 and TB1000 reported their content as not systematically consistent with the products' own former descriptions.2,3,7

    The catch

    Three gaps stack here, and each is enough on its own: the molecule studied in the human trials is the 43-residue protein, the route studied is an eye drop or a topical dressing rather than an injection, and the indication studied is not a musculoskeletal one. On top of that, the 2023 supply analysis means a safety or efficacy profile cannot reliably be attached to what is actually in circulation.

    Sold for laboratory use. Not a legal medicine for people.

  4. GHK-Cu (copper tripeptide-1)

    Research use only
    Animal only

    Evidence strength: Animal only. Rodent or cell studies. Nothing published in humans.

    What it is

    A three-amino-acid copper-binding peptide, long used in topical skin products and increasingly sold as an injectable for tissue repair.

    What the evidence shows

    A 2026 orthopaedic review of therapeutic peptides groups GHK-Cu with BPC-157 and TB-500 as wound-healing peptides that promote angiogenesis, integrin-mediated matrix remodelling and fibroblast activation, and states that clinical trials are currently lacking across the compounds it covers.3

    The catch

    As of August 2026 a ClinicalTrials.gov intervention search for GHK-Cu returns two studies: a 60-participant phase 2 of a topical gel on standardised punch-biopsy skin wounds, recruiting since February 2026 with estimated completion in March 2028, and a not-yet-recruiting study of circulating GHK levels. Both concern skin. Neither lists a tendon, ligament or muscle injury, and neither has posted results.

    Sold for laboratory use. Not a legal medicine for people.

  5. CJC-1295, ipamorelin and sermorelin

    Compounding restricted
    Animal only

    Evidence strength: Animal only. Rodent or cell studies. Nothing published in humans.

    What it is

    Growth-hormone-releasing peptides, sold on the reasoning that a higher growth hormone and IGF-1 signal accelerates repair after an injury.

    What the evidence shows

    A 2026 orthopaedic review describes these secretagogues as activating IGF-1 signalling and satellite-cell repair, alongside a stated lack of clinical trials. A 2026 sports medicine review reports the same for the unapproved peptides it examined: favourable animal results, scarce rigorous human safety data, and potential for serious harm to patients.2,3

    The catch

    As of August 2026 a ClinicalTrials.gov intervention search returns three studies for ipamorelin — post-operative ileus, gastrointestinal dysmotility, and one listing PTSD, cognitive dysfunction and brain injury — and one for CJC-1295, terminated in 2006. None lists a tendon, ligament or muscle injury. Both compounds are also banned in sport, and peptide compounding is under active FDA restriction.

    Under active FDA restriction — compliant pharmacies decline to sell it.

The shape of the evidence

Thirty-six studies. Thirty-five in animals. One retrospective series of twelve people 4. That is the BPC-157 literature as a 2025 systematic review found it, and the same shape repeats down this page: mechanism established in rodents, with human outcome data that is either absent or drawn from a different tissue by a different route.

This is not a criticism of the animal work, which is consistent and mechanistically coherent. It is a statement about what that work can tell you. Compounds that improve tendon healing in rats routinely fail to do so in people; that is a normal result in drug development, not an unlucky one.

What changed in 2026

For years the honest line was that no registered trial tested these compounds in a real sports injury. That is no longer accurate. As of August 2026, a ClinicalTrials.gov intervention search returns a 120-participant phase 2 trial of BPC-157 in acute hamstring muscle strain, recruiting since February 2026, with time to return to unrestricted sport and MRI-assessed injury volume as its primary endpoints and an estimated completion date in February 2028. A phase 2 of topical GHK-Cu gel on standardised skin wounds started the same month, completing in 2028.

Neither has posted results. Both are worth watching, and neither tells you anything yet.

The molecule you buy is not the molecule studied

This trips up more readers than any other point on the page. TB-500 is a seven-residue fragment; the human trials belong to the 43-residue protein 3. The route differs too — the phase 3 evidence is an eye drop 6, and TB-500 is sold as an injection.

Then there is the supply. A 2023 analysis of internet-sold TB500 and TB1000 products found their content not systematically consistent with the products' own former descriptions 7. Our TB-500 page and BPC-157 page go through both problems in detail.

What would change this page

Results from the hamstring trial, or an equivalent randomized trial with a healing or return-to-play endpoint. Until one reports, the 2025 narrative review's position stands: robust preclinical effects, minimal human data, and a compound that should be treated as investigational 5. The 2026 orthopaedic primer reached the same conclusion from its own search — human orthopaedic data lacking, indications and duration unknown 1. The same compounds get sold for sleep and recovery, where the evidence is thinner still.

Questions

Frequently asked questions

Does BPC-157 actually heal tendons?

In rodents, the evidence is consistent — a 2025 systematic review found improved functional, structural and biomechanical outcomes across muscle, tendon, ligament and bone models. In people, that review found one clinical entry: a retrospective series in which 7 of 12 patients reported relief lasting over six months after intra-articular injection for chronic knee pain. A 120-participant phase 2 trial in acute hamstring strain began recruiting in February 2026 and is estimated to complete in February 2028.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein; TB-500 is the seven-residue segment at positions 17 to 23, synthesised with an acetyl group added. The published human trials belong to the full protein, mostly as an eye drop. A 2026 orthopaedic review describes human orthopaedic data as lacking for both.

Are any of these approved or legal to prescribe?

For a musculoskeletal injury, none of them. Peptide compounding is under active FDA restriction, so compliant pharmacies decline to supply the affected compounds, and a 2026 orthopaedic review notes that thymosin beta-4 and TB-500 are banned substances in sport. Research use only is a legal shipping category, not a quality standard.

What is the risk if the animal data is that good?

Two separable risks. The first is the compound itself: a 2026 sports medicine review states that rigorous human safety data are scarce across the unapproved peptides it examined, with potential for serious harm. The second is the supply — a 2023 analysis of internet-sold TB500 and TB1000 products found their contents not systematically consistent with their own descriptions, which means neither efficacy nor safety can be attached to what actually arrives.

Keep reading

Go deeper on one compound

BPC-157

Full trial-by-trial evidence review.

TB-500

Full trial-by-trial evidence review.

Sources

References

  1. Mayfield CK, Bolia IK, Feingold CL, et al. (2026). Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/41476424/
  2. Mendias CL, Awan TM (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/41966639/
  3. Rahman OF, Lee SJ, Seeds WA (2026). Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. JAAOS Global Research & Reviews. https://pubmed.ncbi.nlm.nih.gov/41490200/
  4. Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. https://pubmed.ncbi.nlm.nih.gov/40756949/
  5. McGuire FP, Martinez R, Lenz A, et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. https://pubmed.ncbi.nlm.nih.gov/40789979/
  6. Sosne G, Kleinman HK, Springs C, et al. (2022). 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/36613994/
  7. Delcourt V, Garcia P, Chabot B, et al. (2023). TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Testing and Analysis. https://pubmed.ncbi.nlm.nih.gov/36482504/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.